Aeterna Zentaris Inc

AEZS-CA:Toronto Stock Exchange
*Data is delayed | CAD
Last | 3:59 PM EST
0.97quote price arrow up+0.07 (+7.78%)
Volume
233,961
52 week range
0.37 - 2.00

...

Loading . . .

KEY STATS

  • Open0.92
  • Day High1.01
  • Day Low0.89
  • Prev Close0.90
  • 52 Week High2.00
  • 52 Week High Date01/21/20
  • 52 Week Low0.37
  • 52 Week Low Date11/02/20
  • Market Cap39.39M
  • Shares Out62.68M
  • 10 Day Average Volume269,006
  • Dividend-
  • Dividend Yield-
  • Beta2.14
  • 1 Year % Change-48.13

RATIOS/PROFITABILITY

  • EPS (TTM)-0.24
  • P/E (TTM)-4.01
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Aeterna Zentaris Inc News

There is no recent news for this security.

Latest AEZS-CA News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses...
Carolyn Egbert Ph.D., J.D.
Chairman
Klaus Paulini Ph.D.
President
Leslie Auld
Chief Financial Officer
Nicola Ammer
Vice President
Matthias Gerlach
Vice President
Guenther Grau
Vice President - Finance
Address
41st, 1155 Rene-Levesque Blvd W Flr 4000
Montreal, QC
H3B 3V2
Canada